{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:05:41Z","timestamp":1787655941520,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jiac.2019.08.017","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T21:03:58Z","timestamp":1573765438000},"page":"230-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting"],"prefix":"10.1016","volume":"26","author":[{"given":"Hiroko","family":"Tsukada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Tsuruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Ogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawasuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2019.08.017_bib1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/AAC.45.6.1919-1922.2001","article-title":"In\u00a0vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers","volume":"45","author":"Barry","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/j.1875-9114.1988.tb04076.x","article-title":"Therapeutic update on glycopeptide and lipopeptide antibiotics","volume":"8","author":"Rotschafer","year":"1988","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2019.08.017_bib3","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1128\/AAC.00230-13","article-title":"Couet WRoblot F Pharmacokinetics of daptomycin in a patient with severe renal failure not receiving dialysis","volume":"57","author":"Marchand","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2217\/17460913.1.3.255","article-title":"Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria","volume":"1","author":"Johnson","year":"2006","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jiac.2019.08.017_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European cubicin((R)) outcomes registry and experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jiac.2019.08.017_bib6","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Novelli APai MP Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.08.017_bib7","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A\u00a0multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.08.017_bib9","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1128\/AAC.48.8.2799-2807.2004","article-title":"Knebel WKastrissios H Population pharmacokinetics of daptomycin","volume":"48","author":"Dvorchik","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.45.3.845-851.2001","article-title":"Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection","volume":"45","author":"Louie","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"Andes DCraig WA in\u00a0vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2146\/ajhp130527","article-title":"Benziger DPatel HN Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels","volume":"71","author":"Burdette","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2019.08.017_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2019.08.017_bib14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"DeBruin MFArbeit RD Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijid.2017.01.017","article-title":"Evaluation of pharmacokinetics and the stability of daptomycin in serum at various temperatures","volume":"57","author":"Ogami","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2019.08.017_bib16","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/jac\/dkn414","article-title":"Lovering AMMacgowan AP an HPLC assay for daptomycin in serum","volume":"62","author":"Tobin","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DWGault","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jiac.2019.08.017_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10156-008-0623-2","article-title":"The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility","volume":"14","author":"Niki","year":"2008","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10156-009-0674-Z","article-title":"Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens' antibacterial susceptibility","volume":"15","author":"Niki","year":"2009","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10156-011-0214-5","article-title":"Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens' antibacterial susceptibility","volume":"17","author":"Niki","year":"2011","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10156-012-0434-3","volume":"18","author":"Watanabe","year":"2012","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1128\/AAC.00350-06","article-title":"Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm","volume":"51","author":"Raad","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical A World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2019.08.017_bib24","first-page":"45","article-title":"International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human u ICH harmonized tripartite guideline: guideline for Good Clinical Practice","volume":"47","year":"2001","journal-title":"J\u00a0Postgrad Med"},{"key":"10.1016\/j.jiac.2019.08.017_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Paterson DLLipman J Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2019.08.017_bib26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2019.08.017_bib27","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Lai JJTally FP Once-daily dosing in dogs optimizes daptomycin safety","volume":"44","author":"Oleson","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American heart association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jiac.2019.08.017_bib29","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jiac.2019.08.017_bib30","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2019.01.011","article-title":"Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients","author":"Urakami","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib32","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/AAC.02967-15","article-title":"Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations","volume":"60","author":"Bhavnani","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"A\u00a0Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"Asin-Prieto","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2019.08.017_bib34","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1086\/504379","article-title":"Winstead PSMurphy BS Rhabdomyolysis during therapy with daptomycin","volume":"42","author":"Papadopoulos","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.08.017_bib35","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/cid\/ciw815","article-title":"Patel NSteed ME comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2019.08.017_bib36","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19302661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X19302661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:00:32Z","timestamp":1761159632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X19302661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1341321X19302661"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2019.08.017","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2019.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}